Background

Small-cell lung cancer (SCLC) is a highly aggressive disease with dismal prognosis (1). Given its tendency to early develop widespread metastases, in approximatively two-thirds of cases SCLC is diagnosed at extensive-stage (ES). Standard treatment for ES-SCLC has remained unchanged for years. In the first-line setting, 4–6 cycles of chemotherapy with a platinum-based drug (either cisplatin or carboplatin) plus etoposide has represented the treatment of choice for three decades (2,3) whereas the combination of a platinum-based drug plus irinotecan has been considered an acceptable option, widely used in Japan (4). Despite high response rate of about 60–70% with first-line platinum-based chemotherapy, however, most patients inevitably experience progressive disease within 6 months, and median overall survival (OS) does not exceed 10 months (2-4). For patients with relapsed disease, topotecan is recognized as a standard treatment. However, topotecan achieves modest response rates of 17% in platinum-sensitive and only 5% in platinum-refractory disease, with median OS of about 3–4 months (5). Other treatments such as irinotecan, temozolomide and anthracycline-based regimens have also shown similar activity to topotecan in the second-line setting (1).

Recently, new insights into the biology of SCLC have revealed novel potential therapeutic targets including immune checkpoints, developmental regulatory pathways and DNA damage response (DDR) pathways (6-8). In such evolving context, the identification of reliable biomarkers is a crucial challenge for laying the foundation of personalized medicine in SCLC (8).

High tumor mutational burden (TMB) induced by tobacco exposure is generally observed in SCLC and it certainly represents a strong rationale for immunotherapy. In fact, in the phase I/II CheckMate-032 study, nivolumab monotherapy and the combination of nivolumab plus ipilimumab showed promising antitumor activity and durable responses in pretreated patients, with median OS of 4.1 and 7.9 months respectively (9). Interestingly, an exploratory analysis reported an impressive median OS of 22 months for patients with high TMB treated with nivolumab plus ipilimumab (10). In the randomized, phase I/III IMpower133 study, the addition of atezolizumab to standard first-line carboplatin and etoposide extended median PFS from 4.3 to 5.2 months and median OS from 10.3 to 12.3 months as compared with carboplatin and etoposide plus placebo, thus becoming a standard option for first-line treatment (11). In this study, however, no association between blood-based TMB levels and the benefit of atezolizumab was found. Several ongoing clinical trials are currently investigating the role of immune checkpoint inhibitors and combinations in first-line, second-line and as maintenance therapy and possibly they also will further explore TMB as a biomarker for patients receiving immunotherapy.

Among developmental regulatory pathways, Notch is the most promising candidate as therapeutic target (6). Particularly, delta-like protein 3 (DLL3), an inhibitory...
Notch ligand involved in the embryonal development of central nervous system, is highly upregulated in SCLC but it is not expressed in normal adult tissues, thus representing an ideal target and also a potential biomarker. A phase I trial on patients with recurrent metastatic SCLC treated with rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate that specifically targets DLL3, reported a response rate of 17% and a median OS of 4.6 months in the overall population (12). Among the 29 patients with high expression of DLL3, defined as detectable protein expression by immunohistochemistry in ≥50% of tumor cells, the activity of Rova-T was remarkable with a response rate of 35% and a median OS of 5.8 months. Notably, only patients with high DLL3 expression achieved an objective response, and this observation supports the role of DLL3 expression as a predictive biomarker for Rova-T. Based on these results, in the phase II TRINITY study (13) Rova-T was further investigated as third-line or later-line treatment for patients with DLL3-positive SCLC (defined as SCLC with DLL3 expression in ≥25% of tumor cells). In this study on heavily pretreated patients, investigator-assessed response rate was 18% and median OS was 5.6 months, with better outcomes reported for patients treated in third-line and with higher levels of DLL3 expression (≥75% of tumor cells). Rova-T is currently under evaluation in two phase III trials as second-line treatment and as maintenance therapy respectively, and it is also being investigated in combination with chemotheraphy and with checkpoint inhibitors in phase I trials.

In the past few years, growing evidence have also suggested the therapeutic opportunity of targeting DDR in SCLC (7,8). Most cases of SCLC harbor inactivating mutations in TP53 and RB genes as well as amplification of the oncogenic transcription factors MYC and SOX-1, thus resulting in frenetic cell proliferation and relevant DNA replication stress (7). In this context of genomic instability, survival of cancer cells is highly dependent on functional DDR and cell cycle checkpoints. Particularly the poly-ADP-ribose polymerase (PARP) enzymes play a key role in DDR primarily through the break excision repair (BER) pathway and they are more frequently upregulated in SCLC as compared to normal lung or NSCLC (8). Based on this background, PARP inhibition in SCLC could directly lead to tumor cell death or potentiate the cytotoxic effect of other anticancer drugs (7,8). Therefore, PARP inhibitors have been actively investigating in SCLC, both as single agents and in combination with other anticancer drugs (Table 1).

**Temozolomide plus veliparib for relapsed SCLC**

On August 2018, *Journal of Clinical Oncology* published the results of a randomized, double-blind, phase II study of temozolomide in combination with veliparib or placebo in patients with relapsed SCLC, by Pietanza and colleagues (14).

Temozolomide is an oral alkylating agent that produces O6-alkyl-guanine lesions on DNA, which are removed by the DNA-repair enzyme O6-methylguanine DNA methyltransferase (MGMT). Left unrepaird, temozolomide-induced DNA damage leads to DNA double-strand breaks, with subsequent inhibition of DNA replication and trigger of cell apoptosis. In a previous study, single-agent temozolomide had demonstrated activity in patients affected by relapsed SCLC with a response rate of 20% in the overall population, higher for patients with methylated MGMT compared to those with unmethylated MGMT (38% vs. 7%, P=0.008). However, the benefit obtained by single-agent temozolomide was short, with a median duration of response of 3.5 months and a median OS of 6 months, possible due to development of early resistance (15). It is well known that PARP-dependent BER pathway is involved in resistance to temozolomide, and this provided the rationale for investigating the combination of the PARP inhibitor veliparib plus temozolomide, with the aim to overcome resistance.

In this study, 104 patients with recurrent SCLC were randomized 1:1 to receive veliparib or placebo 40 mg twice daily on days 1–7, plus temozolomide 200 mg/m2/day on days 1–5 of a 28-day cycle (14). After the first 24 patients were enrolled in the trial, grade 3/4 hematologic toxicity was reported in 14 patients (included a case of grade 4 febrile neutropenia leading to sepsis and death in the temozolomide/veliparib arm), therefore protocol was amended to reduce temozolomide at 150 mg/m2/day in order to avoid myelosuppression and treatment delays. Primary endpoint of the study was improvement of PFS at 4 months in patients receiving temozolomide/veliparib compared with temozolomide/placebo. Secondary objectives were response rate and OS, and exploratory objectives included PARP-1 and Schlafen-11 (SLFN11) immunohistochemical expression, MGMT promoter methylation, circulating tumor cells (CTCs) quantification and mutation analysis in DDR genes.

Formally, this was a negative study since 4-month PFS was not significantly improved in the temozolomide/veliparib arm compared with temozolomide/placebo arm (36% vs. 27%, P=0.19) (14). Median OS also was not
significantly different between the two arms (8.2 versus 7.0 months; P=0.50). Even if the temozolomide/veliparib combination achieved higher response rate compared with temozolomide/placebo (39% vs. 14%, P=0.016), this came at the cost of higher hematologic toxicity, particularly grade 3/4 thrombocytopenia (50% vs. 9%), grade 3/4 neutropenia (31% vs. 7%), and febrile neutropenia (4% vs. 0%). As the authors themselves mentioned in the discussion section of the paper, hematologic toxicities were often observed early in the temozolomide/veliparib arm thus leading to treatment delays, and this may potentially explain the lack of benefit with the combination. Another possible explanation for the negative results lies in the dose levels chosen for veliparib and temozolomide. In this trial, in fact, veliparib was given at low dose on the basis of the results of a phase II study in breast cancer (16) and temozolomide was given at the full recommended dose in SCLC, whereas more recent data suggested that, on the contrary, the optimal synergy may be achieved with a near-maximal dose of PARP inhibitors plus a submaximal dose of temozolomide.

Although this was a negative study, interesting data came from the exploratory biomarker analysis (14). Briefly, PARP-1 expression did not correlate with outcome. No definitive conclusion could be drawn on the role of MGMT promoter methylation as well as on the role of mutations in DDR genes, due to the low number of tissue samples analyzed (32 samples and 22 samples, respectively, for MGMT methylation analysis and targeted sequencing of DDR genes). A prognostic rather than predictive role was suggested for CTCs, given that elevated levels (≥ 5 CTCs) both at baseline and after first cycle were associated with worse OS at the univariable analysis.

The most relevant results of the biomarker analysis involved SLFN11 (14). SLFN11 is a DNA/RNA helicase that is actively recruited to the sites of DNA damage and regulates replication stress (8). Preclinical data indicated

<table>
<thead>
<tr>
<th>Study identifier</th>
<th>Study phase</th>
<th>Setting</th>
<th>Estimated enrollment (pts)</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02289690</td>
<td>I/II, randomized</td>
<td>1st-line ES-SCLC</td>
<td>221</td>
<td>Carboplatin + etoposide + veliparib vs. carboplatin + etoposide</td>
</tr>
<tr>
<td>NCT01642251</td>
<td>I/II, randomized</td>
<td>1st-line ES-SCLC and metastatic neuroendocrine NSCLC</td>
<td>157</td>
<td>Cisplatin + etoposide + veliparib vs. cisplatin + etoposide + placebo</td>
</tr>
<tr>
<td>NCT03516084</td>
<td>III, randomized</td>
<td>Maintenance after 1st-line chemotherapy for ES-SCLC</td>
<td>591</td>
<td>Niraparib vs. placebo</td>
</tr>
<tr>
<td>NCT02899728</td>
<td>II, randomized</td>
<td>Maintenance after 1st-line chemotherapy for ES-SCLC</td>
<td>132</td>
<td>Cediranib + olaparib</td>
</tr>
<tr>
<td>NCT02769962</td>
<td>I/II</td>
<td>Recurrent ES-SCLC</td>
<td>138</td>
<td>CRLX101 + olaparib</td>
</tr>
<tr>
<td>NCT03227016</td>
<td>I/II</td>
<td>Recurrent ES-SCLC</td>
<td>130</td>
<td>Topotecan + veliparib</td>
</tr>
<tr>
<td>NCT02446704</td>
<td>I/II</td>
<td>Recurrent ES-SCLC</td>
<td>106</td>
<td>Temozolomide + olaparib</td>
</tr>
<tr>
<td>NCT03672773</td>
<td>II</td>
<td>Recurrent ES-SCLC</td>
<td>28</td>
<td>Low-dose temozolomide + talazoparib</td>
</tr>
<tr>
<td>NCT03428607</td>
<td>II</td>
<td>Recurrent ES-SCLC</td>
<td>45</td>
<td>AZD6738 + olaparib</td>
</tr>
<tr>
<td>NCT02511795</td>
<td>Ib</td>
<td>Recurrent ES-SCLC</td>
<td>135</td>
<td>AZD1775 + olaparib</td>
</tr>
<tr>
<td>NCT02937818</td>
<td>II</td>
<td>Recurrent ES-SCLC</td>
<td>91</td>
<td>Durvalumab + tremelimumab, AZD1775 + carboplatin, AZD6738 + olaparib</td>
</tr>
<tr>
<td>NCT03009682</td>
<td>II</td>
<td>Recurrent ES-SCLC with HR pathway mutations</td>
<td>28</td>
<td>Olaparib</td>
</tr>
<tr>
<td>NCT02734004</td>
<td>I/II</td>
<td>Solid tumors (including SCLC)</td>
<td>288</td>
<td>Olaparib + MEDI4736 +/- bevacizumab</td>
</tr>
<tr>
<td>NCT02498613</td>
<td>II</td>
<td>Solid tumors (including SCLC)</td>
<td>126</td>
<td>Cediranib + olaparib</td>
</tr>
</tbody>
</table>

PARP, poly-ADP-ribose polymerase; ES, extensive-stage; SCLC, small-cell lung cancer; NSCLC, non-small cell lung cancer; HR, homologous recombination.
SLFN11 as a candidate marker of sensitivity to DNA-damaging chemotherapy and PARP inhibitors. Particularly, among 63 SCLC and 3 NSCLC cell lines, high SLFN11 expression was found to be associated with sensitivity to PARP inhibitors (17). This finding was further confirmed in vivo on SCLC patient-derived xenograft models (18). Based on these findings, with a protocol amendment the immunohistochemistry assessment of SFLN11 was included in the exploratory objectives of the study (14). Among 48 tumor samples evaluated for SFLN11 expression 23 were SFLN11-positive (H-score ≥1) and 25 were SFLN11-negative (H-score <1). In terms of response rate, there was no significant difference on the basis of SLFN11 expression, in either study arms. However, patients with SFLN-positive tumors treated with temozolomide/veliparib had prolonged PFS (5.7 vs. 3.6 months, P=0.009) and OS (12.2 vs. 7.5 months, P=0.014) compared to those with SFLN11-negative tumors, whereas no difference in terms of PFS or OS were observed in the temozolomide/placebo arm on the basis of SLFN11 expression. The reason for a PFS and OS benefit without an increase in objective response for patients with SLFN11-positive tumors treated with temozolomide/veliparib is not completely clear, but a trend towards deeper responses and also possibly a longer duration of response may represent an explanation.

Despite the limitations of the assessment of SLFN11 in this study, including its exploratory nature and the limited sample size (less than 50% of patients enrolled in the study were assessed for SLFN11), the median OS of approximatively 12 months reported for patients with SLFN11-positive disease is impressive (14), and the consistency between the preclinical background and clinical trial results increase the plausibility that SLFN11 may represent a predictive biomarker for PARP inhibitors in SCLC.

Conclusions

Immune checkpoint inhibitors and antibody-drug conjugates have recently entered the treatment landscape of SCLC, and other agents are on horizon. In particular, PARP inhibitors are being tested in a number of clinical trials recruiting more than one-thousand patients. Possibly, a biomarker-driven selection of patients could improve clinical trial results. In this perspective, the data reported by Pietanza and colleagues are extremely relevant. For the first time in a clinical trial, in fact, it was observed that high expression if SLFN11 could serve as predictive biomarker of effectiveness of PARP inhibitors in SCLC. This finding, however, derived from an exploratory analysis on a limited sample size and warrants further investigation. If the predictive role of SLFN11 will be confirmed in well-designed biomarker validation studies, it could represent an important step towards personalized medicine in SCLC.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883-95.


